SPD489 (Lisdexamfetamine dimesylate)
SPD489-119
Phase 1 small_molecule completed
Quick answer
SPD489 (Lisdexamfetamine dimesylate) for Schizophrenia is a Phase 1 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Schizophrenia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed